Our technology
How it works
Our technology provides proprietary RNA agents with liver-targeting drug delivery vehicles to restore hemostasis by precisely modulating the endogenous expression of clotting proteins in the blood.
.svg)
Proprietary RNA sequences are developed to target disease causing proteins specific to each disease.
Sequences are encapsulated in proprietary lipid nanoparticles (LNP) for drug delivery.
RNA-LNP therapies are administered to patients via injection.
RNA-LNPs therapies localize to the liver, modulating protein expression to correct disordered coagulation.
8
patented assets
Our diverse portfolio of targets and technologies offer a suite of novel approaches for addressing the complex drivers of coagulation. We have eight patented assets in development ranging from discovery to late preclinical phase.